Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
05/2005
05/31/2005US6900214 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
05/31/2005US6900205 Antidiabetic agents
05/31/2005US6900202 Nicotinic acetylcholine receptor activators; treating neurodegenerative disorders
05/31/2005US6900201 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
05/31/2005US6900200 Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
05/31/2005US6900182 Inositolphosphoglycan and ribose for treatment of ischaemia-reperfusion injury
05/31/2005US6900178 Protection against ischemia and reperfusion injury
05/31/2005US6900177 Anticholesterol agents; cardiovascular disorders
05/31/2005US6900043 Phosphatases which activate map kinase pathways
05/31/2005US6900038 eNOS mutations useful for gene therapy and therapeutic screening
05/31/2005US6900031 Endothelial and Smooth muscle cell-Derived Neuropilin-like molecule; effective in restenosis after percutaneous transluminal coronany angioplasty and arterial sclerosis
05/31/2005US6900020 Identifying prorenin modulators for treatment of cardiovascular and organ hypertrophy; enzyme inhibitors; mimetics
05/31/2005US6900008 Methods and formulations for minimizing spasticity in blood vessel grafts
05/31/2005US6899867 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol)
05/31/2005US6899723 Transcutaneous photodynamic treatment of targeted cells
05/26/2005WO2005046689A2 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity
05/26/2005WO2005046680A1 Percutaneous absorption type cerebral protective agent
05/26/2005WO2005046623A1 Combined cosmetic or therapeutic preparation
05/26/2005WO2005028438A9 Novel piperidine derivative
05/26/2005WO2005027951B1 Method for controlling angiogenesis in animals
05/26/2005WO2005000318B1 Method of inducing apoptosis and inhibiting cardiolipin synthesis
05/26/2005WO2003004039A9 Composition comprising soy and use thereof in the prevention and/or treatment of various diseases
05/26/2005US20050113580 2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-dephenylethyl)amino]propoxy}phenyl)-ethanol; agonists of the nuclear receptors, LXR alpha and LXR beta used to increase ABCA1, ABCG1, and apolipoprotein E expression and inhibiting cholesterol absorption
05/26/2005US20050113577 Such as hydrochloride salt 3-[5-(4-methanesulfonyl-piperazin-1-yl-methyl)-1H-indol-2-yl]-1H-quinolin-2-one; signal transduction; for treatment of angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, and inflammatory diseases
05/26/2005US20050113451 7-acetamidinyl derivatives
05/26/2005US20050113440 Compounds that modulate PPAR activity and methods for their preparation
05/26/2005US20050113422 5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-2,3-dihydro-indol-1-yl}-acetic acid methyl ester or an oxazole analogous compound; side effect reduction; non-insulin dependent diabetes; hypoglycemic agents; obesity; hyperlipemia; anticholesterol agents; atherosclerosis
05/26/2005US20050113416 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
05/26/2005US20050113402 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
05/26/2005US20050113383 For therapy of allergy, allergy-induced airway responses, congestion, hypotension, cardiovascular disease, hypotension, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastrointestinal tract, obesity, sleep
05/26/2005US20050113377 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase, 2 (COX-2) inhibitors
05/26/2005US20050113370 Therapeutic substituted indazole derivatives
05/26/2005US20050113368 eg (+-) Ethyl 3-[4-{3-(3,4-dihydro-2H-benzo[b][1,4]oxazin-4-yl)propylamino}phenyl]-2-ethoxypropanoate; antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic
05/26/2005US20050113367 Mixture of angiotensin II receptor antagonist and diuretics (a thiazide); hypotensive agents; low toxicity
05/26/2005US20050113362 Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
05/26/2005US20050113361 Amide derivatives as NMDA receptor antagonists
05/26/2005US20050113360 NMDA (N-methyl-D-aspartate) receptors; eg 6-(4-benzylpiperidin-1-carbonyl)-1,5-dihydro-oxazolo[4,5-f]indole-2-one
05/26/2005US20050113359 NMDA (N-methyl-D-aspartate) receptors; eg 1-[4-(4-fluoro-benzyl)-piperidin-1-yl]-1-(6-hydroxy-1H-indole-2-yl)methanone
05/26/2005US20050113358 Enzyme inhibitors for erectile dysfunction and sexual disorders
05/26/2005US20050113322 Oligonucleotides which hybridize to inhibit expression; nucleosides; chimera; colloids; cardiovascular disorders; nervous system disorders; diabetes; ischemia/reperfusion injuries
05/26/2005US20050113314 For treating microalbuminuria, nephropathies, retinopathies, and erectile dysfunction; side effect reduction
05/26/2005US20050113312 2-0-(-d-glucopyranosyl) ascorbic acid, process for its production, and foods and cosmetics containning compositions comprising it
05/26/2005US20050113299 Protein a compositions and methods of use
05/26/2005US20050113291 Use of a substance which binds to and initiates signaling of the human SARP-1 receptor or a substance which stimulates release or potentiates the activity of endogenous SARP-1 for the manufacture of a medicament for the treatment and/or prevention of scleroderma, in particular of systemic sclerosis
05/26/2005US20050113284 Drug for regenerating tissue and vessel and method therefor
05/26/2005US20050112725 Secreted and transmembrane polypeptides and nucleic acids encoding the same
05/26/2005US20050112675 Polypeptides gene expressed in fat tissue ; measurement concentration; using antibodies
05/26/2005US20050112575 Nucleic acid sequence encoding polypeptides; triggering calcium oscillation in ooctyes ; determination fertility
05/26/2005US20050112574 Isolated nucleic acid; angiogenesis inhibitor
05/26/2005US20050112568 Dgks as modifiers of the p53 pathwha and methods of use
05/26/2005US20050112565 Proteases
05/26/2005US20050112206 Mixture of drug, aminoacrylate polymer and acid
05/26/2005US20050112187 Nucleic acid that expresses a polypeptide such as a cytokine and a phospholipid, both having cytotoxic activity; synergistic combination; side effect reduction
05/26/2005US20050112110 Isolated polynucleotide sequences; controlling neovasculization; cell growth regulators
05/26/2005US20050112101 Methods of treating restenosis
05/26/2005CA2545364A1 Methods of modulating angiogenesis and cancer cell proliferation
05/26/2005CA2545060A1 Methods of use of thrombin receptor antagonists
05/26/2005CA2544309A1 Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
05/26/2005CA2544252A1 Stem cell culture medium and method of using said medium and the cells
05/26/2005CA2543806A1 Combined cosmetic or therapeutic preparation
05/26/2005CA2543582A1 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity
05/25/2005EP1533619A2 Specific markers for metabolic syndrome
05/25/2005EP1533374A1 Novel peptides having camp producing activity
05/25/2005EP1533318A1 Prodrugs of thrombin inhibitors
05/25/2005EP1533312A1 Hetero-bicyclic compounds
05/25/2005EP1533305A1 A process for the preparation of valsartan and intermediates thereof
05/25/2005EP1533294A1 Beta-alanine derivative and use thereof
05/25/2005EP1533292A1 Dibenzylamine compound and medicinal use thereof
05/25/2005EP1532987A1 Agents for gene therapeutic for cerebrovascular disorders
05/25/2005EP1532974A2 Aqueous gel comprising 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
05/25/2005EP1532269A2 1l1rl-1 as a cardiovascular disease marker and therapeutic target
05/25/2005EP1532251A1 Human acid sensing ion channel 2b (hasic2b), process for producing the same, and its use
05/25/2005EP1532242A2 Methods for preparing purified prostaglandin e synthase
05/25/2005EP1532238A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
05/25/2005EP1532153A1 Azepinoindole and pyridoindole derivatives as pharmaceutical agents
05/25/2005EP1532147A1 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity
05/25/2005EP1532145A1 Pyrazole compositions useful as inhibitors of gsk-3
05/25/2005EP1532144A1 Novel quinuclidine derivatives and their use
05/25/2005EP1532140A1 Thienylhydrazon with digitalis-like properties ( positive inotropic effects )
05/25/2005EP1532135A1 Nf-kb inhibitors
05/25/2005EP1532133A1 Nf-:b inhibitors
05/25/2005EP1532122A1 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
05/25/2005EP1532121A1 New use of pyrimidine - or triazine- 2-carbonitiles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitile derivatives
05/25/2005EP1532111A1 2,5-disubstituted 3-mercaptopentanoic acid
05/25/2005EP1532108A2 Structural carotenoid analogs for the inhibition and amelioration of disease
05/25/2005EP1532104A1 Crystalline beta-2 adrenergic receptor agonist
05/25/2005EP1532103A2 Use of compounds having an amine nucleus in manufacture of a medicament useful for treating factor viia-associated conditions
05/25/2005EP1531906A1 Novel screens to identify agents that modulate retinal blood vessel function and pericyte function and diagnostic and therapeutic application therefor
05/25/2005EP1531879A1 Use of organic compounds
05/25/2005EP1531870A1 Selected cell delivery for heart failure
05/25/2005EP1531865A2 Methods and compositions for the repair and/or regeneration of damaged myocardium
05/25/2005EP1531857A1 Metalloproteinase inhibitors
05/25/2005EP1531856A1 Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
05/25/2005EP1531847A2 Pharmaceutical formulation
05/25/2005EP1531831A1 Fosinopril formulation
05/25/2005EP1531830A1 Method for reducing c-rective protein levels with non-antibacterial tetracycline formulations
05/25/2005EP1531817A1 Glycinamide derivatives as raf-kinase inhibitors
05/25/2005EP1531815A1 Glucokinase activators
05/25/2005EP1531812A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis
05/25/2005EP1531809A1 At1-receptor antagonists for preventing secondary strokes
1 ... 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 ... 1595